Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data.
Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning.
Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company, announced its participation at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023, at 2:00 p.m. Eastern Time in Toronto, Ontario. Key executives, including President and CEO David R. Parkinson, COO Peter Virsik, and CFO David S. Wood, will engage in one-on-one meetings with investors.
The conference connects U.S. and Canadian investors with updates on the Canadian healthcare sector and features both presentations and private meetings with prominent companies. A live webcast of ESSA's presentation will be available on the company’s website, with an archived version accessible for 90 days thereafter.
ESSA Pharma Inc. (NASDAQ: EPIX) announced a clinical trial support agreement with Janssen Research & Development to evaluate EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with apalutamide and abiraterone acetate plus prednisone for prostate cancer treatment. The Phase 1 trial will assess safety, pharmacokinetics, and anti-tumor activity in metastatic castration-resistant prostate cancer (mCRPC) and high-risk metastatic castration-sensitive prostate cancer (mCSPC) patients. ESSA retains all rights to EPI-7386, which has received Fast Track designation from the FDA. Preliminary data indicate a favorable safety profile and early signs of anti-tumor activity.
